As artificial intelligence drives an unprecedented surge in electricity demand, one utility company—Constellation Energy—is uniquely positioned with its vast nuclear fleet to meet the need, turning an industry-wide bottleneck into a significant growth opportunity.
Asset managers ramped up bearish bets against the U.S. dollar to their highest level in months, only to be blindsided by a sudden rally fueled by speculation that former Fed Governor Kevin Warsh is President Trump's pick to lead the central bank.
The Northern Ireland Executive has suspended a planned revaluation of hotel business rates, averting significant tax increases for accommodation providers slated for 2026 and providing temporary stability for the region's tourism industry.
Glaukos Corporation's iDose TR glaucoma therapy receives a key FDA labeling update, permitting repeat administration. While the news bolsters the company's growth narrative, analysts are divided on whether its current stock price already reflects future potential amid rich valuation metrics.
Goldcom's (GOLD) shares have soared nearly 90% in the past year, leaving investors to grapple with a critical question: has the market already priced in all the good news, or is there still room to run? A deep dive into the valuation metrics reveals a stark contradiction.
With shares of the global sustainability leader up nearly 7x over three years, investors are grappling with a critical question: has the market run too far ahead of fundamentals? A deep dive into valuation metrics suggests caution may be warranted.
Lantronix's new partnership to develop edge AI threat detection systems for drones has spotlighted the stock, but analysts are divided on whether its current valuation fully prices in the risks and opportunities of the nascent defense tech market.
Idorsia's exclusive licensing agreement with EMS to commercialize insomnia drug QUVIVIQ across Latin America marks a key step in its global expansion. The deal, involving $20 million in milestones and royalties, arrives as long-term data for its Fabry disease candidate lucerastat puts the spotlight on the company's broader late-stage pipeline and persistent financial pressures.
Bayer's share price has more than doubled in the past 12 months, yet key valuation models suggest a significant gap remains between its market price and intrinsic value. We examine the metrics behind the rally and the lingering legal and portfolio challenges facing the company.
The home improvement giant is eliminating approximately 800 corporate positions and mandating a full-time return to office, while simultaneously launching new AI tools for professionals and expanding its organic seed offerings nationwide, signaling a dual focus on operational efficiency and future-facing customer engagement.
As China's pork industry grapples with overcapacity and falling prices, a growing appetite for premium, flavorful black pork among the middle class is offering a lifeline to farmers and reshaping market strategies.
While Boeing's Q4 revenue beat offers short-term relief, analysts point to its unprecedented order backlog as the true indicator of long-term recovery and growth potential in the commercial aviation sector.
As Smurfit Westrock navigates the complex post-merger landscape, its share price tells a conflicted story. While recent gains hint at optimism, a deeper look reveals a stock trading at a significant discount to some intrinsic value models, even as its P/E ratio suggests a premium. The market appears to be weighing integration execution risks against long-term synergy potential.
A reported fiery exchange between JPMorgan's Jamie Dimon and Coinbase's Brian Armstrong at the World Economic Forum lays bare the intensifying battle between traditional finance and the crypto industry over regulation, deposits, and the future of money.
Meta CEO Mark Zuckerberg's forecast of a major AI infrastructure build-out through 2026 suggests continued robust spending on Nvidia's hardware, reinforcing the chipmaker's central role in the ongoing tech boom.
The Biden administration has approved a major arms sale to Israel, featuring attack helicopters and armored vehicles, amid a fragile ceasefire in Gaza and ongoing scrutiny over U.S. military support.
In a rare firsthand account, Dr. Mohamed Ibrahim details his three-day escape from el-Fasher as paramilitary forces overran the city. His testimony paints a harrowing picture of urban warfare, civilian slaughter, and the systematic collapse of Sudan's last army bastion in Darfur.
Exclusive testimony from Dr. Mohamed Ibrahim, who fled the last hospital in Sudan's strategic el-Fasher, details a three-day ordeal of hiding from paramilitary forces, witnessing mass casualties, and surviving a kidnapping and ransom demand—shedding light on a siege the U.N. calls a 'massive crime scene.'
New long-term results from the pivotal EMBARK trial indicate ELEVIDYS, Sarepta's gene therapy, continues to alter the disease trajectory for boys with Duchenne muscular dystrophy, with no new safety concerns emerging over three years.
Amid a brutal year for apparel stocks, Deckers Outdoor delivered a stunning earnings beat, sending shares soaring 19%. The performance of its HOKA and UGG brands, coupled with raised guidance, suggests Wall Street's pessimism may have been overblown for this long-term winner.
